Table 3.
Effect of capsule wall coatings on the mean drug deposition and aerosolization performance of CC1-3Dm at a 4 kPa pressure drop. Coefficient of variation (%) is shown in parenthesis [n=3].
| Description | EEG formulation |
L-leucine | Magnesium stearate |
|---|---|---|---|
| Emitted (%)* | 65.3 (3.9) | 67.8 (2.6) | 72.9 (1.6)** |
| Capsule retention (%)* | 14.2 (12.5) | 12.7 (10.7) | 9.2 (23.9)** |
| Capsule chamber retention (%) | 7.8 (34.1) | 6.7 (17.8) | 6.9 (7.3) |
| Mouthpiece retention (%) | 12.7 (28.7) | 12.9 (10.1) | 11.0 (14.6) |
| FPF<5µm/ED (%) | 95.4 (0.4) | 95.2 (0.7) | 94.4 (0.4) |
| FPF<1µm/ED (%) | 38.1 (3.7) | 36.6 (4.0) | 36.0 (1.6) |
| MMAD (µm) | 1.29 (2.75) | 1.33 (2.50) | 1.35 (0.88) |
*
P<0.05 significant effect of capsule wall coatings with EEG formulation, L-leucine and magnesium stearate on % emitted and capsule retention (one-way ANOVA).
**
P<0.05 significant effect of % emitted and capsule retention compared to capsule wall coated with EEG formulation (post-hoc Tukey).
Batch-2 EEG formulation combination particles generated by Büchi Nano Spray Dryer (B-90).